Elanco(ELAN) Prnewswire·2025-01-27 13:06Core Insights - Elanco Animal Health has launched Zenrelia, a once-daily oral JAK inhibitor for dogs suffering from allergic dermatitis, which was approved by the FDA in September 2024 [1][2][12] - Approximately 17 million dogs in the U.S. are affected by allergic skin diseases, highlighting a significant market opportunity for effective treatments like Zenrelia [1][2] - A clinical trial involving over 300 allergic dogs demonstrated Zenrelia's effectiveness compared to the leading JAK inhibitor, Apoquel [2][8] Company Overview - Elanco Animal Health is a global leader in animal health, focusing on innovative products and services for disease prevention and treatment in both farm animals and pets [11] - The company emphasizes its commitment to improving animal health and creating value for various stakeholders, including pet owners and veterinarians [11] Product Details - Zenrelia is indicated for controlling itching and inflammation associated with skin allergies in dogs over 12 months of age [12] - The product is designed to start working from the first dose, providing quick relief for dogs suffering from allergic itch [2][4] Market Impact - A survey indicated that 82% of pet owners with itchy dogs are eager for effective treatment solutions, suggesting a strong demand for products like Zenrelia [4] - Real-world results from pet owners show significant improvements in their dogs' conditions after using Zenrelia, reinforcing its market potential [4][9] Clinical Evidence - A newly published study in Veterinary Dermatology compared the clinical outcomes of Zenrelia and Apoquel, providing scientific backing for Zenrelia's efficacy [2][8] - Veterinarians have reported positive outcomes in their patients after using Zenrelia, indicating its acceptance in the veterinary community [10]